ANTIBODIES

CancerTools.org: The home for cancer research tools

Back

Anti-CD19 [4G7]

Cat. #153512

Tool name: Anti-CD19 [4G7]
Alternate names: B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, Differentiation antigen CD19, T-cell surface antigen Leu-12
Clone: 4G7
Tool type: Antibodies
Tool sub-type: Primary antibody
Class: Monoclonal
Conjugate: Unconjugated
Reactivity: Human
Host: Mouse
Application: ELISA ; FACS ; IHC ; WB
Description: CD19 assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought. CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.
Immunogen: CD19
Isotype: IgG1
Research area: Cancer; Cell biology; Cell signaling and signal transduction; Immunology

Target: CD19
Target background: CD19 assembles with the antigen receptor of B-lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 is a hallmark of B-cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B-cell lymphomas.Since 2011 treatments targeting CD19 have begun to enter trials. Most current experimental anti-CD19 drugs in development work by exploiting the presence of CD19 to direct treatment specifically towards B-cell cancers. However, it is now emerging that the protein plays an active role in driving the growth of these cancers, most intriguingly by stabilizing the concentrations of the myc oncoprotein. This suggests that CD19 and its downstream signaling may be a more attractive therapeutic target than originally thought. CD19 has also been implicated in autoimmune diseases and may be a useful treatment target.

Quantity:

For any enquiries, please, contact us .